广元市智能美甲加盟电话多少钱(葫芦岛市瞧享美甲加盟电话多少钱) (今日更新中)

The U.S. reported 2,473 deaths caused by COVID-19 on Tuesday, the highest number of deaths linked to the virus in a single day since the height of the pandemic in May.According to the COVID Tracking Project, the nearly 2,500 deaths are the most the U.S. has seen since May 7 — the deadliest day of the pandemic thus far, when 2,769 COVID-19 deaths were reported.Tuesday also marked the sixth-deadliest day since the pandemic began.Deaths linked to COVID-19 have been on the rise since October — though the 7-day rolling average of deaths linked to the virus has dipped in recent days, likely due to a lack of reports from the Thanksgiving holiday. From Oct. 1 to Dec. 1, the 7-day average of reported COVID-19 deaths has more than doubled from 705 to 1,520. The rise in deaths mirrors a frightening rise in COVID-19 cases. According to the COVID Tracking Project, the U.S. has recorded at least 100,000 new cases of the virus every day since Nov. 3. Since that time, the rolling 7-day average of new cases has nearly doubled from about 85.000 a day to about 159,000 a day.And health experts expect deaths and caseloads to further increase in the coming weeks. Dr. Deborah Birx, a member of the White House coronavirus task force, says the U.S. finds itself in a "very dangerous place" following the Thanksgiving holiday. She says anyone who attended a Thanksgiving gathering last week should assume they are infected with COVID-19 and take appropriate precautions. With more than a million Americans boarding airplanes on Sunday alone following the Thanksgiving holiday, health experts fear cases will skyrocket in the coming days.They also expect hospitals — already overtaxed by current COVID-19 caseloads — to admit even more patients with the virus. Currently, the COVID Tracking Project reports that 99,000 Americans are hospitalized with the virus, forcing some facilities to institute overflow areas. 1925

The winning numbers for Tuesday night's Mega Millions .6 billion jackpot are 28, 70, 5, 62, 65 with Mega Ball 5.No one in the California won the entire jackpot Tuesday night, but several tickets did match five of six numbers, the state lottery says. Eight of those tickets sold in San Luis Obispo, Stockton, Rancho Cucamonga, San Diego, Chatsworth, Arcadia, Norwalk and San Francisco. The near-winning ticket in San Diego sold at a Chevron gas station in Del Cerro.  491

The revolution is coming. The much-anticipated video premiere of “Hamilton” will be available on Disney+ Friday, July 3.Here are the details: The video is 2 hours and 41 minutes long, and includes a minute countdown for intermission. It was recorded using several cameras during two of the last performances of the initial 2016 Broadway run of the hit musical, and includes most of the original cast.It will only be available on the Disney+ streaming service starting at 12 a.m. PT/3 a.m. ET on Friday. Disney is holding a Twitter watch party later in the day at 7 p.m. ET/4 p.m. PT. 591

The video streaming service Netflix has been indicted by a grand jury in Texas over the film “Cuties,” alleging the company used “lewd” images."Cuties" is a French film that follows the story of an 11-year-old Senegalese immigrant in France who rebels against her family's Muslim traditions and joins a free-spirited dance crew.The film, directed by Ma?mouna Doucouré and originally called “Mignonnes”, won a directing award at Sundance Film Festival earlier this year.A Tyler County, Texas grand jury moved to return an indictment against Netflix last month, according to multiple media reports.The complaint alleges Netflix knowingly promoted visual material which “depicts the lewd exhibition of the genitals or public area of a clothed or partially clothed child who was younger than 18 years of age at the time the visual material was created, which appeals to the prurient interest in sex, and has no serious, literary, artistic, political, or scientific value.”In response, Netflix stated “‘Cuties’ is a social commentary against the sexualization of young children,” according to a statement in Deadline. “This charge is without merit and we stand by the film.”Netflix was reportedly served a summons October 1.Earlier this summer Netflix was forced to apologize for what they called “inappropriate art work” used to promote the movie on their service.The main image Netflix originally used shows the four lead actresses, all girls, wearing black and turquoise dance outfits revealing their stomachs and most of their legs, while posed mid-dance.The images used in France for the film show the girls walking down the street holding shopping bags.The film is recommended for 16+, according to Netflix. The image and description for the film have been updated in Netflix.The poster sparked outrage online, and with some comparing the poster to pedophilia. In the days following the release of the artwork, thousands had signed a Change.org petition calling for the film to be removed from Netflix. The film is now available on the service.Doucouré said the film is based in part on her own childhood experiences, and those of girls growing up today.“This is most of all an uncompromising portrait of an 11-year-old girl plunged in a world that imposes a series of dictates on her.” She said in an interview with Cineuropa.She continued that it is important to not judge these girls, but to understand them, listen to them and give them a voice. 2458

The U.S. regulators who will decide the fate of COVID-19 vaccines are taking an unusual step: Asking outside scientists if their standards are high enough.The Food and Drug Administration may have to decide by year’s end whether to allow use of the first vaccines against the virus. Thursday, a federal advisory committee pulls back the curtain on that decision process, debating whether the guidelines FDA has set for vaccine developers are rigorous enough.“We will not cut corners, and we will only use science and data to make that determination,” FDA Commissioner Stephen Hahn pledged at a meeting of the Milken Institute Wednesday.Exactly how much data his agency needs to be sure a vaccine is safe and effective is a key question for the advisers. An even bigger one: If the FDA allows emergency use of a vaccine before final testing is finished, will that destroy chances of ever learning just how well that shot -- and maybe competitors still being studied -- really work?“We can’t lose sight of the fact that it is in our societal interest to see these trials to completion,” said Dr. Luciana Borio, a former FDA acting chief scientist who will be watching the advisers’ debate.Plus, multiple vaccines are being studied -- shots made with different technologies that each have pros and cons.“The first vaccine is not necessarily the best vaccine,” cautioned Dr. M. Miles Braun, a former FDA scientist now with Georgetown University School of Medicine. If the trials aren’t allowed to finish, it may be difficult or impossible to ever know for sure.It’s a critical moment in FDA’s 114-year history. The government has spent billions to race a vaccine through a research process that usually takes years, and FDA faces unprecedented pressure from the Trump administration, fueling public skepticism that politics could overrule science.Interest is so high, FDA is airing the meeting on YouTube. Here are some key issues the committee will discuss:HOW MUCH EVIDENCE IS NEEDED?FDA is requiring manufacturers to do studies of at least 30,000 people to prove if a vaccine protects and how safe it is. Those studies must include adequate numbers of people at highest risk from COVID-19 -- older adults, minorities and anyone with underlying health problems.FDA has made clear that any vaccine must be at least 50% effective. And while the studies are designed to run for two years, companies may get enough evidence the shots are protective -- in at least some people -- to stop the trials early and seek what’s called an “emergency use authorization” for wider vaccinations.Despite White House objections, the FDA told vaccine makers earlier this month not to seek that speedier review until they’ve tracked at least half their trial participants for two months. With other vaccines, that’s about the amount of time when major side effects crop up.That’s not long enough, said the head of the non-profit ECRI Institute, which reviews medical technology for hospitals and insurers. In comments submitted to the advisory committee, ECRI’s Dr. Marcus Schabacker said FDA should require six months of follow-up.“Doing any less would simply risk too much, and the consequences may be severe,” he wrote. “A weak vaccine that loses public trust could poison the well for epidemic control for many years.”WOULD EMERGENCY USE DERAIL FULL ANSWERS ABOUT VACCINES?Normally when a study ends because of evidence that a vaccine is working, the participants who got dummy shots are offered the real thing.But if FDA allows emergency use of a COVID-19 vaccine, that’s not the same as having full proof the shot works, Borio cautioned.And if the participants in the placebo group are immediately offered the real shot, researchers may not be able to get answers about all the high-risk groups in the study — or tell how long the vaccine’s protection lasts, a process expected to take many more months.But Pfizer Inc., which with Germany’s BioNTech is developing one of the leading candidates, told FDA that if it’s granted emergency use authorization, it “would have an ethical obligation” to alert study participants who got a placebo and allow them vaccine access. The company wants FDA to look into “other scientifically and statistically sound methods” to determine long-term safety and effectiveness.Pfizer’s stance is likely to face pushback. The Infectious Diseases Society of America states that FDA’s panelists “should insist” that vaccine developers “present a compelling case” for how they will complete their trials if FDA grants early authorization of their vaccine.Clearing a vaccine based on premature or faulty data “could cause more harm” by “further eroding public confidence in all vaccines,” the group said.It’s an unprecedented dilemma. The FDA has previously allowed emergency use of only one vaccine, a decades-old shot that in 2005 was authorized to prevent anthrax poisoning.This time around, multiple COVID-19 vaccines are in the pipeline. Pfizer competitor Johnson & Johnson cautioned that early FDA clearance of one vaccine could “jeopardize integrity” of other ongoing trials if patients decide to drop out to seek the first cleared shot instead.The company asked regulators to explain what options are available to ensure completion of all ongoing COVID-19 vaccine trials.WHAT ABOUT LONG-TERM SAFETY MONITORING?Even a study of 30,000 people cannot spot a side effect that only strikes 1 in 100,000. So the government is planning extra scrutiny of every COVID-19 vaccine to hit the market.At first there will be limited doses given to just certain high-risk people -- and those early recipients are to get text messages daily for the first week after vaccination, and then weekly out to six weeks, asking how they’re feeling.FDA also will be checking databases of electronic health records and insurance claims, looking for any red flags.“There’s a kind of tracking that has to take place here on a massive basis that hasn’t taken place before,” said Dr. Jesse Goodman of Georgetown University, a former director of the FDA’s vaccine and biologics center.___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education. The AP is solely responsible for all content. 6274

来源：资阳报